Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 2/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180288 | 0.94 | PYGL (0.35) | PYGLPDE10ANPY1RCMA1 | |
| SCHEMBL19969008 | 0.94 | PYGL (0.35) | PYGLPDE10ANPY1RCMA1 | |
| SCHEMBL19969164 | 0.88 | PDE10A (0.34) | PYGLPDE10ACMA1 | |
| SCHEMBL19962037 | 0.88 | PDE10A (0.34) | PYGLPDE10ACMA1 | |
| SCHEMBL19962086 | 0.87 | CMA1 (0.35) | PYGLPDE10ACMA1NTSR1 | |
| SCHEMBL19962038 | 0.85 | PIN1 (0.39) | PYGLPDE10APIN1 | |
| SCHEMBL19962065 | 0.85 | NOS2 (0.33) | PYGLPDE10A | |
| SCHEMBL19962014 | 0.83 | PYGL (0.36) | PYGLPDE10APIN1 | |
| SCHEMBL19962042 | 0.83 | PYGL (0.34) | PYGLPDE10APIN1 | |
| SCHEMBL19969114 | 0.83 | NPY1R (0.35) | PYGLPDE10ANPY1RCMA1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | PYGL 498/4885PDE10A 2805/4885NPY1R 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.